Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:Treatment satisfaction and limitations in haemophilia A, with a focus on factor VIII product storage conditions : patients’ perspectives and challenges
Avtorji:ID Preložnik Zupan, Irena (Avtor)
ID Rener, Karla (Avtor)
ID Anžej Doma, Saša (Avtor)
Datoteke:.pdf PDF - Predstavitvena datoteka, prenos (742,99 KB)
MD5: 185447C8C8953108A1F463135775CBB8
 
URL URL - Izvorni URL, za dostop obiščite https://link.springer.com/article/10.1007/s40267-022-00967-x#Abs1
 
Jezik:Angleški jezik
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:Logo UKC LJ - Univerzitetni klinični center Ljubljana
Povzetek:Introduction Prophylaxis with factor VIII (FVIII) concentrates is the mainstay of treatment for haemophilia A; however, patients’ perceptions of treatment can negatively affect compliance and treatment outcomes. Aim The aim of this study was to explore treatment limitations and satisfaction in haemophilia A from the patient’s perspective, with a focus on product storage characteristics. Methods Patients with haemophilia A in Slovenia completed a survey focussing on treatment satisfaction and understanding of FVIII product storage conditions. Patient satisfaction with product storage was analysed using the Kano model. Results There were 63 survey respondents in total (note: not all patients answered all questions). Most patients were aged > 18 years (93.6%), had severe haemophilia A (68.3%) and were on FVIII prophylaxis (73.8%). The mean (median) number of bleeds in the previous 12 months was 4.9 (3.0). Missed, forgotten or delayed doses were reported by 46.4% of all patients and by 53.3% of patients on prophylaxis. Most patients believed FVIII products should be stored at ≤ 25 °C (90.7%) or only in a refrigerator (53.7%). Additionally, 76.4% of patients reported limitations in daily activities (especially travel) due to product storage requirements. Survey results and Kano model analysis indicated that treatment satisfaction may be improved by a product that can be stored at > 25 °C. Conclusion This survey highlights patient perspectives regarding treatment satisfaction and limitations in haemophilia A, with a focus on product storage conditions. Perceived product storage requirements limit the daily activities of many patients (especially travel). Ongoing patient education is necessary to improve treatment satisfaction, compliance, treatment outcomes and overall health.
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Leto izida:2023
Št. strani:str. 71-80
Številčenje:Vol. 39, iss.
PID:20.500.12556/DiRROS-32150 Novo okno
UDK:616.1
ISSN pri članku:1172-0360
DOI:10.1007/s40267-022-00967-x Novo okno
COBISS.SI-ID:136098051 Novo okno
Datum objave v DiRROS:28.08.2026
Število ogledov:138
Število prenosov:72
Metapodatki:XML DC-XML DC-RDF
:
Kopiraj citat
  
Objavi na:Bookmark and Share



Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:Drugs & therapy perspectives
Skrajšan naslov:Drugs & ther. perspect.
Založnik:Adis International
ISSN:1172-0360
COBISS.SI-ID:15436293 Novo okno

Licence

Licenca:CC BY-NC 4.0, Creative Commons Priznanje avtorstva-Nekomercialno 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by-nc/4.0/deed.sl
Opis:Licenca Creative Commons, ki prepoveduje komercialno uporabo, vendar uporabniki ne rabijo upravljati materialnih avtorskih pravic na izpeljanih delih z enako licenco.

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:hematologija, hemofilija A, faktor VIII


Nazaj